Ciba-Geigy Corporation

Emergent Product Development Gaithersburg Inc.

Novartis Corporation

Ucp Gen-Pharma Ag

Novartis Ag

Evolva Sa

Ciba-Geigy Corporation a Corp. of New York

Jutta Heim

Bernd Meyhack

Peter Schneider

Patrick Roussel

Christian Bartels

Daniel Milligan

Glenn E Dale

Fredericus A Asselbergs

Yaoquan Liu

Sefik Alkan

Bhabatosh Chaudhuri

Jan Van Oostrum

Rolf Burgi

Gabriele Pohlig

Bhanu Rajput

Thomas Hottiger

Peter Furst

Jacob B Visser

Christof Gysler

Hans Fritz

Hermanus C Kester

Walter M&auml;rki

Dieter Heinrich Wolf

Christian Sommerhoff

Czeslaw Czendlik

Giancarlo Agnelli

Hansjorg Treichler

Jochen Kuhla

Kenji Takabayashi

Glen Dale

Disclosed herein are compounds of Formula I 

2-pyridone antimicrobial compositions

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Antimicrobial 4-oxoquinolizines

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof. 

A method for the production and secretion of proteins with hirudin activity in an eukaryotic host organism is provided. There are also provided hybrid vectors comprising a DNA sequence encoding a signal peptide upstream of and in reading frame with the structural gene for desulphatohirudin, and eukaryotic host organisms transformed with said hybrid vectors.

Production of thrombin inhibitors

A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.

Production of polypeptides by use of novel protease deficient yeast

The invention concerns a method for the production of a polypeptide with the aid of genetically engineered yeast cells which contain not more than one functional CUP1 gene in the genome and carry a plasmid comprising a gene coding for said polypeptide and a functional CUP1 gene; and said yeast cells and said plasmids.

Process for the production of polypeptides

The present invention relates to novel inhibitors belonging to the family of antistasin-type serine proteinase inhibitors, to their isolation from the medical leech Hirudo medicinalis, to DNA sequences encoding the novel inhibitors, to variants obtained by recombinant DNA technology or peptide synthesis, pharmaceutical compositions containing the inhibitors, and to their use in diagnosis and therapy.

Antistasin type serine protease inhibitors

A novel process for the production of recombinant desulphatohirudin by transformed yeast strains is provided. The process makes use of an expression cassette comprising the yeast CUP1 promoter. The invention concerns also said transformed yeast strains, novel expression vectors and methods for the production thereof.

Process for the production of protease inhibitors

Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Hybrid plasminogen activator

Recombinant DNA molecules coding for pectin lyase (PL) expression systems and derivatives thereof, such as the structural genes of PLA, PLB, PLC, PLD, PLE and PLF, and corresponding regulatory sequences, e.g. promoter, signal and terminator sequences, and hybrid vectors comprising corresponding DNAs, including hybrid vectors with DNA coding for homologous or heterologous polypeptides, hosts, especially filamentous fungi, e.g. Aspergillus hosts, transformed by said vectors, methods for the preparation of said recombinant DNA molecules and said hosts and the use of the recombinant DNA molecules for the preparation of new expression systems. A further objective is the preparation of polypeptides by means of said DNAs and said hosts.

Pectin lyase genes of aspergillus niger

The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.

Pharmaceutical compositions comprising modified and unmodified

DNA molecules encoding hybrid proteins of tissue plasminogen activator

Novel human plasminogen activators of the urokinase type are produced by yeast cells transformed with a hybrid vector comprising a DNA sequence coding for said human plasminogen activator. Novel hybrid vectors, yeast hosts transformed with such hybrid vectors and processes for the production thereof are also provided. 77

Process for the production of urokinase using Saccharomyes cerevisiae

There is provided a pharmaceutical composition comprising as component A a plasminogen activator and as component B hirudin together with a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the prophylaxis and therapy of thrombosis or diseases caused by thrombosis.

Growing community of inventors

Ramlinsburg, Switzerland

Jutta Heim